146 related articles for article (PubMed ID: 28521068)
1. Association of outcomes and anti-Xa levels in the treatment of pediatric venous thromboembolism.
Fan JL; Roberts LE; Scheurer ME; Yee DL; Shah MD; Lee-Kim YJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28521068
[TBL] [Abstract][Full Text] [Related]
2. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
3. Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis.
Pannucci CJ; Prazak AM; Scheefer M
Am J Surg; 2017 Jun; 213(6):1143-1152. PubMed ID: 27692434
[TBL] [Abstract][Full Text] [Related]
4. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
5. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
6. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.
Rojas L; Aizman A; Ernst D; Acuña MP; Moya P; Mellado R; Cerda J
Thromb Res; 2013; 132(6):761-4. PubMed ID: 24521789
[TBL] [Abstract][Full Text] [Related]
7. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
Lin H; Faraklas I; Saffle J; Cochran A
J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.
Pannucci CJ; Fleming KI; Bertolaccini CB; Prazak AM; Huang LC; Pickron TB
JAMA Surg; 2019 Aug; 154(8):697-704. PubMed ID: 31116389
[TBL] [Abstract][Full Text] [Related]
9. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
10. Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose?
Dhillon NK; Smith EJT; Gillette E; Mason R; Barmparas G; Gewertz BL; Ley EJ
Int J Surg; 2018 Mar; 51():128-132. PubMed ID: 29367044
[TBL] [Abstract][Full Text] [Related]
11. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
12. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
Kopelman TR; O'Neill PJ; Pieri PG; Salomone JP; Hall ST; Quan A; Wells JR; Pressman MS
Am J Surg; 2013 Dec; 206(6):911-5; discussion 915-6. PubMed ID: 24296098
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients.
Yam L; Bahjri K; Geslani V; Cotton A; Hong L
Pharmacotherapy; 2019 Jul; 39(7):749-755. PubMed ID: 31112313
[TBL] [Abstract][Full Text] [Related]
14. Weight-Based Enoxaparin for Venous Thromboembolism in Obesity Gives Similar Anti-Xa Levels to Patients <100 kg, with No Increase in Major Bleeding.
Maclachlan KH; Stevens HP; Tran HA; Chunilal SD
Semin Thromb Hemost; 2019 Feb; 45(1):94-99. PubMed ID: 30630208
[TBL] [Abstract][Full Text] [Related]
15. Anti-Xa levels in critically ill children receiving enoxaparin for venothromboembolism prophylaxis.
Marshall AM; Trussell TM; Yee AM; Malone MP
Thromb Res; 2021 Jul; 203():117-120. PubMed ID: 33992874
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
17. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
[TBL] [Abstract][Full Text] [Related]
18. Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience.
Woods GM; Stanek J; Harrison S; Texter K; Kerlin BA; Dunn AL; Kumar R
J Pediatr Hematol Oncol; 2017 Oct; 39(7):576-577. PubMed ID: 28902081
[No Abstract] [Full Text] [Related]
19. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
Deal EN; Hollands JM; Riney JN; Skrupky LP; Smith JR; Reichley RM
J Thromb Thrombolysis; 2011 Aug; 32(2):188-94. PubMed ID: 21465129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]